10-Q 1 antm-20220331.htm 10-Q antm-20220331
false2022Q1000115603912/3126,97125,641136612616100,000,000100,000,0000.010.01900,000,000900,000,000241,140,929241,770,746241,140,929241,770,74625275700011560392022-01-012022-03-3100011560392022-04-13xbrli:shares00011560392022-03-31iso4217:USD00011560392021-12-31iso4217:USDxbrli:shares00011560392021-01-012021-03-3100011560392020-12-3100011560392021-03-310001156039us-gaap:CommonStockMember2021-12-310001156039us-gaap:AdditionalPaidInCapitalMember2021-12-310001156039us-gaap:RetainedEarningsMember2021-12-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001156039us-gaap:NoncontrollingInterestMember2021-12-310001156039srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccountingStandardsUpdate202006Memberus-gaap:RetainedEarningsMember2021-12-310001156039srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccountingStandardsUpdate202006Member2021-12-310001156039srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMemberus-gaap:RetainedEarningsMember2021-12-310001156039srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2021-12-310001156039us-gaap:RetainedEarningsMember2022-01-012022-03-310001156039us-gaap:NoncontrollingInterestMember2022-01-012022-03-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001156039us-gaap:CommonStockMember2022-01-012022-03-310001156039us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001156039us-gaap:CommonStockMember2022-03-310001156039us-gaap:AdditionalPaidInCapitalMember2022-03-310001156039us-gaap:RetainedEarningsMember2022-03-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001156039us-gaap:NoncontrollingInterestMember2022-03-310001156039us-gaap:CommonStockMember2020-12-310001156039us-gaap:AdditionalPaidInCapitalMember2020-12-310001156039srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMemberus-gaap:RetainedEarningsMember2020-12-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001156039us-gaap:NoncontrollingInterestMember2020-12-310001156039srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2020-12-310001156039us-gaap:RetainedEarningsMember2021-01-012021-03-310001156039us-gaap:NoncontrollingInterestMember2021-01-012021-03-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001156039us-gaap:CommonStockMember2021-01-012021-03-310001156039us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001156039us-gaap:CommonStockMember2021-03-310001156039us-gaap:AdditionalPaidInCapitalMember2021-03-310001156039us-gaap:RetainedEarningsMember2021-03-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001156039us-gaap:NoncontrollingInterestMember2021-03-31antm:medical_memberantm:countyantm:statesxbrli:pure0001156039antm:CommercialSpecialtyBusinessSegmentMemberus-gaap:EmployeeSeveranceMember2021-12-310001156039antm:GovernmentBusinessSegmentMemberus-gaap:EmployeeSeveranceMember2021-12-310001156039antm:IngenioRxSegmentMemberus-gaap:EmployeeSeveranceMember2021-12-310001156039antm:OtherSegmentMemberus-gaap:EmployeeSeveranceMember2021-12-310001156039us-gaap:EmployeeSeveranceMember2021-12-310001156039antm:CommercialSpecialtyBusinessSegmentMemberus-gaap:EmployeeSeveranceMember2022-01-012022-03-310001156039antm:GovernmentBusinessSegmentMemberus-gaap:EmployeeSeveranceMember2022-01-012022-03-310001156039antm:IngenioRxSegmentMemberus-gaap:EmployeeSeveranceMember2022-01-012022-03-310001156039antm:OtherSegmentMemberus-gaap:EmployeeSeveranceMember2022-01-012022-03-310001156039us-gaap:EmployeeSeveranceMember2022-01-012022-03-310001156039antm:CommercialSpecialtyBusinessSegmentMemberus-gaap:EmployeeSeveranceMember2022-03-310001156039antm:GovernmentBusinessSegmentMemberus-gaap:EmployeeSeveranceMember2022-03-310001156039antm:IngenioRxSegmentMemberus-gaap:EmployeeSeveranceMember2022-03-310001156039antm:OtherSegmentMemberus-gaap:EmployeeSeveranceMember2022-03-310001156039us-gaap:EmployeeSeveranceMember2022-03-310001156039us-gaap:FixedMaturitiesMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-03-310001156039us-gaap:FixedMaturitiesMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2022-03-310001156039us-gaap:FixedMaturitiesMemberus-gaap:ForeignGovernmentDebtMember2022-03-310001156039us-gaap:FixedMaturitiesMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2022-03-310001156039us-gaap:FixedMaturitiesMemberus-gaap:CorporateDebtSecuritiesMember2022-03-310001156039us-gaap:FixedMaturitiesMemberus-gaap:ResidentialMortgageBackedSecuritiesMember2022-03-310001156039us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FixedMaturitiesMember2022-03-310001156039us-gaap:FixedMaturitiesMemberus-gaap:OtherAggregatedInvestmentsMember2022-03-310001156039us-gaap:FixedMaturitiesMember2022-03-310001156039us-gaap:FixedMaturitiesMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2021-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:ForeignGovernmentDebtMember2021-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2021-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:CorporateDebtSecuritiesMember2021-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:ResidentialMortgageBackedSecuritiesMember2021-12-310001156039us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FixedMaturitiesMember2021-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:OtherAggregatedInvestmentsMember2021-12-310001156039us-gaap:FixedMaturitiesMember2021-12-31antm:securities0001156039us-gaap:ForeignGovernmentDebtMember2021-12-310001156039us-gaap:CorporateDebtSecuritiesMember2021-12-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2021-12-310001156039us-gaap:ForeignGovernmentDebtMember2022-01-012022-03-310001156039us-gaap:CorporateDebtSecuritiesMember2022-01-012022-03-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2022-01-012022-03-310001156039us-gaap:ForeignGovernmentDebtMember2022-03-310001156039us-gaap:CorporateDebtSecuritiesMember2022-03-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2022-03-310001156039us-gaap:CorporateDebtSecuritiesMember2020-12-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2020-12-310001156039us-gaap:CorporateDebtSecuritiesMember2021-01-012021-03-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2021-01-012021-03-310001156039us-gaap:CorporateDebtSecuritiesMember2021-03-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2021-03-310001156039us-gaap:FixedMaturitiesMember2022-01-012022-03-310001156039us-gaap:FixedMaturitiesMember2021-01-012021-03-310001156039us-gaap:ExchangeTradedFundsMember2022-03-310001156039us-gaap:ExchangeTradedFundsMember2021-12-310001156039antm:CommonEquitySecuritiesMember2022-03-310001156039antm:CommonEquitySecuritiesMember2021-12-310001156039us-gaap:PrivateEquityFundsMember2022-03-310001156039us-gaap:PrivateEquityFundsMember2021-12-310001156039us-gaap:EquitySecuritiesMember2022-01-012022-03-310001156039us-gaap:EquitySecuritiesMember2021-01-012021-03-310001156039us-gaap:OtherInvestmentsMember2022-01-012022-03-310001156039us-gaap:OtherInvestmentsMember2021-01-012021-03-310001156039us-gaap:CashMemberus-gaap:MaturityOvernightMember2022-03-310001156039us-gaap:CashMemberus-gaap:MaturityOvernightMember2021-12-310001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:MaturityOvernightMember2022-03-310001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:MaturityOvernightMember2021-12-310001156039us-gaap:MaturityOvernightMemberus-gaap:OtherAggregatedInvestmentsMember2022-03-310001156039us-gaap:MaturityOvernightMemberus-gaap:OtherAggregatedInvestmentsMember2021-12-310001156039us-gaap:CashFlowHedgingMember2022-03-310001156039us-gaap:CashFlowHedgingMember2021-12-310001156039us-gaap:FairValueInputsLevel1Member2022-03-310001156039us-gaap:FairValueInputsLevel2Member2022-03-310001156039us-gaap:FairValueInputsLevel3Member2022-03-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-03-310001156039us-gaap:FixedMaturitiesMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-03-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:FixedMaturitiesMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-03-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2022-03-310001156039us-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2022-03-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:FixedMaturitiesMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2022-03-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMemberus-gaap:ForeignGovernmentDebtMember2022-03-310001156039us-gaap:FixedMaturitiesMemberus-gaap:ForeignGovernmentDebtMemberus-gaap:FairValueInputsLevel2Member2022-03-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:FixedMaturitiesMemberus-gaap:ForeignGovernmentDebtMember2022-03-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2022-03-310001156039us-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2022-03-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:FixedMaturitiesMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2022-03-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMemberus-gaap:CorporateDebtSecuritiesMember2022-03-310001156039us-gaap:FixedMaturitiesMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-03-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:FixedMaturitiesMemberus-gaap:CorporateDebtSecuritiesMember2022-03-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMemberus-gaap:ResidentialMortgageBackedSecuritiesMember2022-03-310001156039us-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ResidentialMortgageBackedSecuritiesMember2022-03-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:FixedMaturitiesMemberus-gaap:ResidentialMortgageBackedSecuritiesMember2022-03-310001156039us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMember2022-03-310001156039us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel2Member2022-03-310001156039us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FixedMaturitiesMember2022-03-310001156039us-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMember2022-03-310001156039us-gaap:OtherDebtSecuritiesMemberus-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel2Member2022-03-310001156039us-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FixedMaturitiesMember2022-03-310001156039us-gaap:OtherDebtSecuritiesMemberus-gaap:FixedMaturitiesMember2022-03-310001156039us-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel1Member2022-03-310001156039us-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel2Member2022-03-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:FixedMaturitiesMember2022-03-310001156039us-gaap:EquitySecuritiesMemberus-gaap:ExchangeTradedFundsMemberus-gaap:FairValueInputsLevel1Member2022-03-310001156039us-gaap:EquitySecuritiesMemberus-gaap:ExchangeTradedFundsMemberus-gaap:FairValueInputsLevel2Member2022-03-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ExchangeTradedFundsMember2022-03-310001156039us-gaap:EquitySecuritiesMemberus-gaap:ExchangeTradedFundsMember2022-03-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel1Memberantm:CommonEquitySecuritiesMember2022-03-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Memberantm:CommonEquitySecuritiesMember2022-03-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberantm:CommonEquitySecuritiesMember2022-03-310001156039us-gaap:EquitySecuritiesMemberantm:CommonEquitySecuritiesMember2022-03-310001156039us-gaap:PrivateEquityFundsMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-03-310001156039us-gaap:PrivateEquityFundsMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-03-310001156039us-gaap:PrivateEquityFundsMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-03-310001156039us-gaap:PrivateEquityFundsMemberus-gaap:EquitySecuritiesMember2022-03-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-03-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-03-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-03-310001156039us-gaap:EquitySecuritiesMember2022-03-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:OtherInvestmentsMemberantm:CommonEquitySecuritiesMember2022-03-310001156039us-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel2Memberantm:CommonEquitySecuritiesMember2022-03-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:OtherInvestmentsMemberantm:CommonEquitySecuritiesMember2022-03-310001156039us-gaap:OtherInvestmentsMemberantm:CommonEquitySecuritiesMember2022-03-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:DerivativeMember2022-03-310001156039us-gaap:DerivativeMemberus-gaap:FairValueInputsLevel2Member2022-03-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeMember2022-03-310001156039us-gaap:DerivativeMember2022-03-310001156039us-gaap:FairValueInputsLevel1Member2021-12-310001156039us-gaap:FairValueInputsLevel2Member2021-12-310001156039us-gaap:FairValueInputsLevel3Member2021-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:FixedMaturitiesMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2021-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2021-12-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:FixedMaturitiesMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2021-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMemberus-gaap:ForeignGovernmentDebtMember2021-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:ForeignGovernmentDebtMemberus-gaap:FairValueInputsLevel2Member2021-12-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:FixedMaturitiesMemberus-gaap:ForeignGovernmentDebtMember2021-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2021-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2021-12-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:FixedMaturitiesMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2021-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMemberus-gaap:CorporateDebtSecuritiesMember2021-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:FixedMaturitiesMemberus-gaap:CorporateDebtSecuritiesMember2021-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMemberus-gaap:ResidentialMortgageBackedSecuritiesMember2021-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ResidentialMortgageBackedSecuritiesMember2021-12-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:FixedMaturitiesMemberus-gaap:ResidentialMortgageBackedSecuritiesMember2021-12-310001156039us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMember2021-12-310001156039us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310001156039us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FixedMaturitiesMember2021-12-310001156039us-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMember2021-12-310001156039us-gaap:OtherDebtSecuritiesMemberus-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310001156039us-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FixedMaturitiesMember2021-12-310001156039us-gaap:OtherDebtSecuritiesMemberus-gaap:FixedMaturitiesMember2021-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:FixedMaturitiesMember2021-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:ExchangeTradedFundsMemberus-gaap:FairValueInputsLevel1Member2021-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:ExchangeTradedFundsMemberus-gaap:FairValueInputsLevel2Member2021-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ExchangeTradedFundsMember2021-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:ExchangeTradedFundsMember2021-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel1Memberantm:CommonEquitySecuritiesMember2021-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Memberantm:CommonEquitySecuritiesMember2021-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberantm:CommonEquitySecuritiesMember2021-12-310001156039us-gaap:EquitySecuritiesMemberantm:CommonEquitySecuritiesMember2021-12-310001156039us-gaap:PrivateEquityFundsMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310001156039us-gaap:PrivateEquityFundsMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310001156039us-gaap:PrivateEquityFundsMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310001156039us-gaap:PrivateEquityFundsMemberus-gaap:EquitySecuritiesMember2021-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310001156039us-gaap:EquitySecuritiesMember2021-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:OtherInvestmentsMemberantm:CommonEquitySecuritiesMember2021-12-310001156039us-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel2Memberantm:CommonEquitySecuritiesMember2021-12-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:OtherInvestmentsMemberantm:CommonEquitySecuritiesMember2021-12-310001156039us-gaap:OtherInvestmentsMemberantm:CommonEquitySecuritiesMember2021-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:DerivativeMember2021-12-310001156039us-gaap:DerivativeMemberus-gaap:FairValueInputsLevel2Member2021-12-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeMember2021-12-310001156039us-gaap:DerivativeMember2021-12-310001156039us-gaap:OtherDebtSecuritiesMember2021-12-310001156039us-gaap:EquitySecuritiesMember2021-12-310001156039us-gaap:OtherDebtSecuritiesMember2022-01-012022-03-310001156039us-gaap:EquitySecuritiesMember2022-01-012022-03-310001156039us-gaap:OtherDebtSecuritiesMember2022-03-310001156039us-gaap:EquitySecuritiesMember2022-03-310001156039us-gaap:OtherDebtSecuritiesMember2020-12-310001156039us-gaap:EquitySecuritiesMember2020-12-310001156039us-gaap:OtherDebtSecuritiesMember2021-01-012021-03-310001156039us-gaap:EquitySecuritiesMember2021-01-012021-03-310001156039us-gaap:OtherDebtSecuritiesMember2021-03-310001156039us-gaap:EquitySecuritiesMember2021-03-310001156039us-gaap:OtherInvestmentsMemberus-gaap:FairValueMeasurementsNonrecurringMember2022-03-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:OtherInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001156039us-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:OtherInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001156039us-gaap:OtherInvestmentsMember2022-03-310001156039us-gaap:FairValueMeasurementsNonrecurringMember2022-03-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001156039us-gaap:OtherInvestmentsMemberus-gaap:FairValueMeasurementsNonrecurringMember2021-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:OtherInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:OtherInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001156039us-gaap:OtherInvestmentsMember2021-12-310001156039us-gaap:FairValueMeasurementsNonrecurringMember2021-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001156039antm:CommercialSpecialtyBusinessSegmentMember2021-12-310001156039antm:GovernmentBusinessSegmentMember2021-12-310001156039antm:OtherSegmentMember2021-12-310001156039antm:CommercialSpecialtyBusinessSegmentMember2022-03-310001156039antm:GovernmentBusinessSegmentMember2022-03-310001156039antm:OtherSegmentMember2022-03-310001156039antm:CommercialSpecialtyBusinessSegmentMember2022-01-012022-03-310001156039antm:GovernmentBusinessSegmentMember2022-01-012022-03-310001156039antm:OtherSegmentMember2022-01-012022-03-310001156039antm:CommercialSpecialtyBusinessSegmentMemberus-gaap:ShortDurationInsuranceContractAccidentYear2020Member2022-03-310001156039antm:CommercialSpecialtyBusinessSegmentMemberus-gaap:ShortDurationInsuranceContractAccidentYear2021Member2022-03-310001156039antm:ShortDurationInsuranceContractAccidentYear2022Memberantm:CommercialSpecialtyBusinessSegmentMember2022-03-310001156039antm:GovernmentBusinessSegmentMemberus-gaap:ShortDurationInsuranceContractAccidentYear2020Member2022-03-310001156039antm:GovernmentBusinessSegmentMemberus-gaap:ShortDurationInsuranceContractAccidentYear2021Member2022-03-310001156039antm:ShortDurationInsuranceContractAccidentYear2022Memberantm:GovernmentBusinessSegmentMember2022-03-310001156039us-gaap:ShortDurationInsuranceContractAccidentYear2020Memberantm:OtherSegmentMember2022-03-310001156039antm:OtherSegmentMemberus-gaap:ShortDurationInsuranceContractAccidentYear2021Member2022-03-310001156039antm:ShortDurationInsuranceContractAccidentYear2022Memberantm:OtherSegmentMember2022-03-310001156039antm:CommercialSpecialtyBusinessSegmentMember2020-12-310001156039antm:GovernmentBusinessSegmentMember2020-12-310001156039antm:OtherSegmentMember2020-12-310001156039antm:CommercialSpecialtyBusinessSegmentMember2021-01-012021-03-310001156039antm:GovernmentBusinessSegmentMember2021-01-012021-03-310001156039antm:OtherSegmentMember2021-01-012021-03-310001156039antm:CommercialSpecialtyBusinessSegmentMember2021-03-310001156039antm:GovernmentBusinessSegmentMember2021-03-310001156039antm:OtherSegmentMember2021-03-310001156039antm:SeniorUnsecuredNotesMember2022-03-310001156039antm:SeniorUnsecuredNotesMember2021-12-310001156039antm:SurplusNotesMember2022-03-310001156039antm:A5YearFacilityMemberus-gaap:RevolvingCreditFacilityMember2022-03-310001156039antm:A5YearFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SubsequentEventMember2022-04-180001156039antm:A2021364DayFacilityMemberus-gaap:SubsequentEventMember2022-04-182022-04-180001156039antm:A2021364DayFacilityMemberus-gaap:RevolvingCreditFacilityMember2022-03-310001156039us-gaap:RevolvingCreditFacilityMember2022-01-012022-03-310001156039us-gaap:LineOfCreditMember2022-03-310001156039us-gaap:CommercialPaperMember2022-03-310001156039us-gaap:CommercialPaperMember2021-12-310001156039us-gaap:ConvertibleDebtMember2022-01-012022-03-310001156039us-gaap:ConvertibleDebtMember2022-03-310001156039us-gaap:FederalHomeLoanBankAdvancesMember2022-03-310001156039antm:SurplusNotesMember2021-12-310001156039us-gaap:FederalHomeLoanBankAdvancesMember2021-12-310001156039srt:MinimumMember2022-03-310001156039srt:MaximumMember2022-03-310001156039antm:BCBSAntitrustLitigationMember2022-03-310001156039antm:AnthemInc.v.ExpressScriptsInc.Memberantm:PharmacypricingMember2022-01-012022-03-310001156039antm:AnthemInc.v.ExpressScriptsInc.Memberantm:OperationalMember2022-01-012022-03-310001156039antm:AnthemInc.v.ExpressScriptsInc.Member2022-01-012022-03-310001156039us-gaap:SubsequentEventMember2022-04-190001156039us-gaap:SubsequentEventMember2022-04-192022-04-1900011560392021-01-260001156039antm:A2020to2022Memberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2021-12-310001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2020-12-310001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2022-01-012022-03-310001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2021-01-012021-03-310001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2022-03-310001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2021-03-310001156039us-gaap:AccumulatedOtherthanTemporaryImpairmentIncludingPortionAttributableToNoncontrollingInterestMember2021-12-310001156039us-gaap:AccumulatedOtherthanTemporaryImpairmentIncludingPortionAttributableToNoncontrollingInterestMember2020-12-310001156039us-gaap:AccumulatedOtherthanTemporaryImpairmentIncludingPortionAttributableToNoncontrollingInterestMember2022-01-012022-03-310001156039us-gaap:AccumulatedOtherthanTemporaryImpairmentIncludingPortionAttributableToNoncontrollingInterestMember2021-01-012021-03-310001156039us-gaap:AccumulatedOtherthanTemporaryImpairmentIncludingPortionAttributableToNoncontrollingInterestMember2022-03-310001156039us-gaap:AccumulatedOtherthanTemporaryImpairmentIncludingPortionAttributableToNoncontrollingInterestMember2021-03-310001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-12-310001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2020-12-310001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-01-012022-03-310001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-01-012021-03-310001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-03-310001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-03-310001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-12-310001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2020-12-310001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-01-012022-03-310001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-01-012021-03-310001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-03-310001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-03-310001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-12-310001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2020-12-310001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-01-012022-03-310001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-01-012021-03-310001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-03-310001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-03-31antm:segment0001156039antm:UnaffiliatedMemberantm:CommercialSpecialtyMember2022-01-012022-03-310001156039antm:UnaffiliatedMemberantm:GovernmentBusinessSegmentMember2022-01-012022-03-310001156039antm:UnaffiliatedMemberantm:IngenioRxSegmentMember2022-01-012022-03-310001156039antm:UnaffiliatedMemberantm:OtherSegmentMember2022-01-012022-03-310001156039antm:UnaffiliatedMember2022-01-012022-03-310001156039antm:IngenioRxSegmentMemberantm:AffiliatedMember2022-01-012022-03-310001156039antm:AffiliatedMemberantm:OtherSegmentMember2022-01-012022-03-310001156039us-gaap:IntersegmentEliminationMember2022-01-012022-03-310001156039antm:AffiliatedMember2022-01-012022-03-310001156039antm:CommercialSpecialtyMember2022-01-012022-03-310001156039antm:GovernmentBusinessSegmentMember2022-01-012022-03-310001156039antm:IngenioRxSegmentMember2022-01-012022-03-310001156039antm:OtherSegmentMember2022-01-012022-03-310001156039antm:UnaffiliatedMemberantm:CommercialSpecialtyMember2021-01-012021-03-310001156039antm:UnaffiliatedMemberantm:GovernmentBusinessSegmentMember2021-01-012021-03-310001156039antm:UnaffiliatedMemberantm:IngenioRxSegmentMember2021-01-012021-03-310001156039antm:UnaffiliatedMemberantm:OtherSegmentMember2021-01-012021-03-310001156039antm:UnaffiliatedMember2021-01-012021-03-310001156039antm:CommercialSpecialtyMemberantm:AffiliatedMember2021-01-012021-03-310001156039antm:GovernmentBusinessSegmentMemberantm:AffiliatedMember2021-01-012021-03-310001156039antm:IngenioRxSegmentMemberantm:AffiliatedMember2021-01-012021-03-310001156039antm:AffiliatedMemberantm:OtherSegmentMember2021-01-012021-03-310001156039us-gaap:IntersegmentEliminationMember2021-01-012021-03-310001156039antm:AffiliatedMember2021-01-012021-03-310001156039antm:CommercialSpecialtyMember2021-01-012021-03-310001156039antm:GovernmentBusinessSegmentMember2021-01-012021-03-310001156039antm:IngenioRxSegmentMember2021-01-012021-03-310001156039antm:OtherSegmentMember2021-01-012021-03-310001156039antm:CommercialSpecialtyBusinessSegmentMemberantm:ManagedCareProductsMember2022-01-012022-03-310001156039antm:CommercialSpecialtyBusinessSegmentMemberantm:ManagedCareProductsMember2021-01-012021-03-310001156039antm:ManagedCareServicesMemberantm:CommercialSpecialtyBusinessSegmentMember2022-01-012022-03-310001156039antm:ManagedCareServicesMemberantm:CommercialSpecialtyBusinessSegmentMember2021-01-012021-03-310001156039antm:CommercialSpecialtyBusinessSegmentMemberantm:DentalVisionProductsAndServicesMember2022-01-012022-03-310001156039antm:CommercialSpecialtyBusinessSegmentMemberantm:DentalVisionProductsAndServicesMember2021-01-012021-03-310001156039antm:CommercialSpecialtyBusinessSegmentMemberantm:OtherProductsMember2022-01-012022-03-310001156039antm:CommercialSpecialtyBusinessSegmentMemberantm:OtherProductsMember2021-01-012021-03-310001156039antm:ManagedCareProductsMemberantm:GovernmentBusinessSegmentMember2022-01-012022-03-310001156039antm:ManagedCareProductsMemberantm:GovernmentBusinessSegmentMember2021-01-012021-03-310001156039antm:ManagedCareServicesMemberantm:GovernmentBusinessSegmentMember2022-01-012022-03-310001156039antm:ManagedCareServicesMemberantm:GovernmentBusinessSegmentMember2021-01-012021-03-310001156039antm:IngenioRxSegmentMemberantm:PharmacyproductsandservicesMember2022-01-012022-03-310001156039antm:IngenioRxSegmentMemberantm:PharmacyproductsandservicesMember2021-01-012021-03-310001156039antm:IntegratedHealthServicesMemberantm:OtherSegmentMember2022-01-012022-03-310001156039antm:IntegratedHealthServicesMemberantm:OtherSegmentMember2021-01-012021-03-310001156039antm:OtherProductsMemberantm:OtherSegmentMember2022-01-012022-03-310001156039antm:OtherProductsMemberantm:OtherSegmentMember2021-01-012021-03-310001156039antm:SegmentEliminationsMember2022-01-012022-03-310001156039antm:SegmentEliminationsMember2021-01-012021-03-310001156039us-gaap:OtherNoncurrentAssetsMember2022-03-310001156039us-gaap:OtherNoncurrentAssetsMember2021-12-310001156039us-gaap:OtherCurrentLiabilitiesMember2022-03-310001156039us-gaap:OtherCurrentLiabilitiesMember2021-12-310001156039us-gaap:OtherNoncurrentLiabilitiesMember2022-03-310001156039us-gaap:OtherNoncurrentLiabilitiesMember2021-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended March 31, 2022
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                     to                     
Commission file number: 001-16751
ANTHEM, INC.
(Exact name of registrant as specified in its charter)
Indiana 35-2145715
(State or other jurisdiction of
incorporation or organization)
 (I.R.S. Employer
Identification Number)
220 Virginia Avenue
Indianapolis, Indiana 46204
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (800331-1476
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common Stock, $0.01 par valueANTMNew York Stock Exchange
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes ☒ No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act:
Large accelerated filer  Accelerated filer
Non-accelerated filer  Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  ☒
As of April 13, 2022, 241,084,780 shares of the Registrant’s Common Stock were outstanding.



Anthem, Inc.
Quarterly Report on Form 10-Q
For the Period Ended March 31, 2022
Table of Contents
 
  Page
PART I. FINANCIAL INFORMATION
ITEM 1.
ITEM 2.
ITEM 3.
ITEM 4.
PART II. OTHER INFORMATION
ITEM 1.
ITEM 1A.
ITEM 2.
ITEM 3.
ITEM 4.
ITEM 5.
ITEM 6.
-1-


PART I. FINANCIAL INFORMATION
ITEM 1.    FINANCIAL STATEMENTS
Anthem, Inc.
Consolidated Balance Sheets
March 31,
2022
December 31,
2021
(In millions, except share data)(Unaudited) 
Assets
Current assets:
Cash and cash equivalents$6,161 $4,880 
Fixed maturity securities (amortized cost of $26,971 and $25,641; allowance for credit losses of $13 and $6)
26,219 26,267 
Equity securities1,662 1,881 
Premium receivables7,349 5,681 
Self-funded receivables3,979 4,010 
Other receivables3,334 3,749 
Other current assets5,193 4,654 
Total current assets53,897 51,122 
Long-term investments:
Fixed maturity securities (amortized cost of $612 and $616; allowance for credit losses of $0 and $0)
596 632 
Other invested assets5,365 5,225 
Property and equipment, net3,986 3,919 
Goodwill24,251 24,228 
Other intangible assets10,588 10,615 
Other noncurrent assets1,803 1,719 
Total assets$100,486 $97,460 
Liabilities and equity
Liabilities
Current liabilities:
Medical claims payable$14,713 $13,518 
Other policyholder liabilities5,396 5,521 
Unearned income1,210 1,153 
Accounts payable and accrued expenses5,493 4,970 
Short-term borrowings275 275 
Current portion of long-term debt3,097 1,599 
Other current liabilities9,549 7,849 
Total current liabilities39,733 34,885 
Long-term debt, less current portion19,883 21,157 
Reserves for future policy benefits811 802 
Deferred tax liabilities, net2,349 2,805 
Other noncurrent liabilities1,679 1,683 
Total liabilities64,455 61,332 
Commitments and contingencies – Note 11
Shareholders’ equity
Preferred stock, without par value, shares authorized – 100,000,000; shares issued and outstanding – none
  
Common stock, par value $0.01, shares authorized – 900,000,000; shares issued and outstanding –
241,140,929 and 241,770,746
2 2 
Additional paid-in capital9,151 9,148 
Retained earnings28,058 27,088 
Accumulated other comprehensive loss(1,236)(178)
Total shareholders’ equity35,975 36,060 
Noncontrolling interests56 68 
Total equity36,031 36,128 
Total liabilities and equity$100,486 $97,460 


See accompanying notes.
-2-


Anthem, Inc.
Consolidated Statements of Income
(Unaudited) 
 Three Months Ended 
 March 31
(In millions, except per share data)20222021
Revenues
Premiums$32,785 $27,676 
Product revenue3,301 2,737 
Administrative fees and other revenue1,800 1,685 
Total operating revenue37,886 32,098 
Net investment income360 291 
Net losses on financial instruments(151)(4)
Total revenues38,095 32,385 
Expenses
Benefit expense28,215 23,699 
Cost of products sold2,883 2,313 
Selling, general and administrative expense4,341 3,925 
Interest expense201 192 
Amortization of other intangible assets129 80 
Total expenses35,769 30,209 
Income before income tax expense
2,326 2,176 
Income tax expense531 509 
Net income1,795 1,667 
Net loss (income) attributable to noncontrolling interests10 (2)
Shareholders’ net income$1,805 $1,665 
Shareholders’ net income per share
Basic $7.48 $6.80 
Diluted $7.39 $6.71 
Dividends per share$1.28 $1.13 

















See accompanying notes.
-3-


Anthem, Inc.
Consolidated Statements of Comprehensive Income
(Unaudited) 
 Three Months Ended 
 March 31
(In millions)20222021
Net income$1,795 $1,667 
Other comprehensive (loss) income, net of tax:
Change in net unrealized losses/gains on investments(1,069)(362)
Change in non-credit component of impairment losses on investments
(1)1 
Change in net unrealized gains/losses on cash flow hedges3 4 
Change in net periodic pension and postretirement costs7 10 
Foreign currency translation adjustments(3) 
Other comprehensive loss(1,063)(347)
Net loss (income) attributable to noncontrolling interests10 (2)
Other comprehensive loss attributable to noncontrolling interests5 2 
Total shareholders’ comprehensive income$747 $1,320 

































See accompanying notes.
-4-


Anthem, Inc.
Consolidated Statements of Cash Flows
(Unaudited)
 Three Months Ended 
 March 31
(In millions)20222021
Operating activities
Net income$1,795 $1,667 
Adjustments to reconcile net income to net cash provided by operating activities:
Net losses on financial instruments151 4 
Equity in net earnings of other invested assets(153)(108)
Depreciation and amortization358 282 
Deferred income taxes(92)31 
Share-based compensation50 64 
Changes in operating assets and liabilities:
Receivables, net(1,348)(1,258)
Other invested assets7 (20)
Other assets(353)(288)
Policy liabilities1,075 1,455 
Unearned income57 (119)
Accounts payable and other liabilities428 358 
Income taxes568 438 
Other, net(2)(1)
Net cash provided by operating activities2,541 2,505 
Investing activities
Purchases of investments(5,050)(6,978)
Proceeds from sale of investments3,047 4,650 
Maturities, calls and redemptions from investments1,209 998 
Changes in securities lending collateral(441)(731)
Purchases of subsidiaries, net of cash acquired(61)(27)
Purchases of property and equipment(254)(204)
Other, net(28)(15)
Net cash used in investing activities(1,578)(2,307)
Financing activities
Net proceeds from (repayments of) commercial paper borrowings225 (250)
Proceeds from long-term borrowings 3,462 
Repayments of long-term borrowings(14) 
Changes in securities lending payable441 731 
Repurchase and retirement of common stock(545)(447)
Cash dividends(309)(277)
Proceeds from issuance of common stock under employee stock plans76 89 
Taxes paid through withholding of common stock under employee stock plans(86)(91)
Other, net534 171 
Net cash provided by financing activities322 3,388 
Effect of foreign exchange rates on cash and cash equivalents(4)(1)
Change in cash and cash equivalents1,281 3,585 
Cash and cash equivalents at beginning of period4,880 5,741 
Cash and cash equivalents at end of period$6,161 $9,326 











See accompanying notes.
-5-


Anthem, Inc.
Consolidated Statements of Shareholders’ Equity
(Unaudited)
 Common StockAdditional
Paid-in
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
(Loss) Income
Noncontrolling
Interests
Total
Equity
(In millions)Number of
Shares
Par
Value
December 31, 2021 (audited)241.8 $2 $9,148 $27,088 $(178)$68 $36,128 
Adoption of Accounting Standards Update 2020-06 (Note 2)— — — (23)— — (23)
January 1, 2022241.8 2 9,148 27,065 (178)68 36,105 
Net income— — — 1,805 — (10)1,795 
Other comprehensive loss— — — — (1,058)(5)(1,063)
Noncontrolling interests adjustment— — — — — 3 3 
Repurchase and retirement of common stock(1.2)— (45)(500)— — (545)
Dividends and dividend equivalents— — — (312)— — (312)
Issuance of common stock under employee stock plans, net of related tax benefits0.5 — 39 — — — 39 
Convertible debenture repurchases, conversions and tax adjustments— — 9 — — — 9 
March 31, 2022241.1 $2 $9,151 $28,058 $(1,236)$56 $36,031 
January 1, 2021245.4 $3 $9,244 $23,802 $150 $ $33,199 
Net income— — — 1,665 — 2 1,667 
Other comprehensive loss— — — — (345)(2)(347)
Accumulated noncontrolling interest— — — — — 65 65 
Repurchase and retirement of common stock(1.4)(1)(53)(393)— — (447)
Dividends and dividend equivalents— — — (281)— — (281)
Issuance of common stock under employee stock plans, net of related tax benefits0.9 — 62 — — — 62 
March 31, 2021244.9 $2 $9,253 $24,793 $(195)$65 $33,918 









See accompanying notes.
-6-


Anthem, Inc.
Notes to Consolidated Financial Statements
(Unaudited)
March 31, 2022
(In Millions, Except Per Share Data or As Otherwise Stated Herein)
 
1.     Organization
References to the terms “we,” “our,” “us” or “Anthem” used throughout these Notes to Consolidated Financial Statements refer to Anthem, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico, unless the context otherwise requires. On March 10, 2022, we announced our intent to change our name to better reflect our business and our journey from a traditional health benefits organization to a lifetime, trusted health partner. At our annual meeting of shareholders on May 18, 2022, our shareholders will vote on a proposed amendment to our amended and restated articles of incorporation to change our name to Elevance Health, Inc. Shareholders of record on March 17, 2022 are entitled to vote. If approved by our shareholders, we expect the name change to occur in the second quarter of 2022.
We are one of the largest health benefits companies in the United States in terms of medical membership, serving nearly 47 million medical members through our affiliated health plans as of March 31, 2022. We offer a broad spectrum of network-based managed care risk-based plans to Individual, Group, Medicaid and Medicare markets. In addition, we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, provider network access, medical management, care management and wellness programs, actuarial services and other administrative services. We also provide services to the federal government in connection with our Federal Health Products & Services business, which administers the Federal Employees Health Benefits (“FEHB”) Program. We provide an array of specialty services both to our subsidiary health plans and also unaffiliated health plans, including pharmacy benefits management (“PBM”) services and dental, vision, life, disability and supplemental health insurance benefits, as well as integrated health services.
We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. In addition, we conduct business through arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve customers in numerous states as AIM Specialty Health, Amerigroup, Aspire Health, Beacon, CareMore, Freedom Health, HealthLink, HealthSun, MMM, Optimum HealthCare, Simply Healthcare, and/or UniCare. We offer PBM services through our IngenioRx, Inc. (“IngenioRx”) subsidiary. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries.
2.     Basis of Presentation and Significant Accounting Policies
Basis of Presentation: The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our 2021 Annual Report on Form 10-K, unless the information contained in those disclosures materially changed or is required by GAAP. In the opinion of management, all adjustments, including normal recurring adjustments, necessary for a fair statement of the consolidated financial statements as of and for the three months ended March 31, 2022 and 2021 have been recorded. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2022, or any other period. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2021 included in our 2021 Annual Report on Form 10-K.
Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (“USD”). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the
-7-


period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in “Foreign currency translation adjustments” in our consolidated statements of comprehensive income.
Cash and Cash Equivalents: We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits, and we have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled $162 and $173 at March 31, 2022 and December 31, 2021, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets.
Investments: We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.
If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security’s cost basis to fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive loss.
The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default.
For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date of the securities. Such adjustments are reported within net investment income.
The changes in fair value of our marketable equity securities are recognized in our results of operations within net gains and losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations, and are reported under the caption “Other invested assets” in our consolidated balance sheets.
We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the caption “Other invested assets” in our consolidated balance sheets.
We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under the caption “Other invested assets” in our consolidated balance sheets.
Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.
-8-


We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. We recognize the collateral as an asset, which is reported under the caption “Other current assets” in our consolidated balance sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported under the caption “Other current liabilities” in our consolidated balance sheets. The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive loss as a separate component of shareholders’ equity. The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments.
Receivables: Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts.
Premium receivables include the uncollected amounts from insured groups, individuals and government programs. Premium receivables are reported net of an allowance for doubtful accounts of $140 and $142 at March 31, 2022 and December 31, 2021, respectively.
Self-funded receivables include administrative fees, claims and other amounts due from self-funded customers. Self-funded receivables are reported net of an allowance for doubtful accounts of $53 and $50 at March 31, 2022 and December 31, 2021, respectively.
Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades, accrued investment income, and other miscellaneous amounts due to us. These receivables are reported net of an allowance for doubtful accounts of $698 and $648 at March 31, 2022 and December 31, 2021, respectively.
Revenue Recognition: For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at March 31, 2022. For the three months ended March 31, 2022 and 2021, revenue recognized from performance obligations related to prior periods, such as due to changes in transaction price, was not material. For contracts that have an original expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.
Recently Adopted Accounting Guidance: In January 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2021-01, Reference Rate Reform (Topic 848) (“ASU 2021-01”). The amendments in ASU 2021-01 provide optional expedients and exceptions for applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of the reference rate reform. The provisions must be applied at a Topic, Subtopic, or Industry Subtopic level for all transactions other than derivatives, which may be applied at a hedging relationship level. We adopted ASU 2021-01 on January 7, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.
In October 2020, the FASB issued Accounting Standards Update No. 2020-08, Codification Improvements to Subtopic 310-20, Receivables—Nonrefundable Fees and Other Costs (“ASU 2020-08”). The amendments in ASU 2020-08 clarify when an entity should assess whether a callable debt security is within the scope of accounting guidance, which impacts the amortization period for nonrefundable fees and other costs. ASU 2020-08 became effective for interim and annual reporting periods beginning after December 15, 2020. The amendments were to be applied on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. We adopted ASU 2020-08 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.
In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting
-9-


for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). The amendments eliminate two of the three accounting models that require separate accounting for convertible features of debt securities, simplify the contract settlement assessment for equity classification, require the use of the if-converted method for all convertible instruments in the diluted earnings per share calculation and expand disclosure requirements. The amendments became effective for our annual and interim reporting periods beginning after December 15, 2021. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective transition method, which resulted in an increase to our reported debt outstanding of $31, a decrease to our deferred tax liabilities of $8, and a corresponding cumulative-effect reduction to our opening retained earnings of $23; the amounts are not material to our overall consolidated financial position. The adoption of ASU 2020-06 did not have an impact on our results of operations or our consolidated cash flows. Use of the if-converted method did not have an impact on our overall earnings per share calculation.
In December 2019, the FASB issued Accounting Standards Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). The amendments in ASU 2019-12 remove certain exceptions to the general principles in Accounting Standards Codification Topic 740. The amendments also clarify and amend existing guidance to improve consistent application. The amendments became effective for our annual reporting periods beginning after December 15, 2020. The transition method (retrospective, modified retrospective, or prospective basis) related to the amendments depends on the applicable guidance, and all amendments for which there is no transition guidance specified are to be applied on a prospective basis. We adopted ASU 2019-12 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.
Recent Accounting Guidance Not Yet Adopted: In November 2020, the FASB issued Accounting Standards Update No. 2020-11, Financial Services—Insurance (Topic 944): Effective Date and Early Application (“ASU 2020-11”). The amendments in ASU 2020-11 make changes to the effective date and early application of Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts (“ASU 2018-12”), which was issued in November 2018. The amendments in ASU 2020-11 have extended the original effective date by one year, and now the amendments are required for our interim and annual reporting periods beginning after December 15, 2022. The amendments in ASU 2018-12 make changes to a variety of areas to simplify or improve the existing recognition, measurement, presentation and disclosure requirements for long-duration contracts issued by an insurance entity. The amendments require insurers to annually review the assumptions they make about their policyholders and update the liabilities for future policy benefits if the assumptions change. The amendments also simplify the amortization of deferred contract acquisition costs and add new disclosure requirements about the assumptions insurers use to measure their liabilities and how they may affect future cash flows. The amendments related to the liability for future policy benefits for traditional and limited-payment contracts and deferred acquisition costs are to be applied to contracts in force as of the beginning of the earliest period presented, with an option to apply such amendments retrospectively with a cumulative-effect adjustment to the opening balance of retained earnings as of the earliest period presented. The amendments for market risk benefits are to be applied retrospectively. We are currently evaluating the effects the adoption of ASU 2020-11 and ASU 2018-12 will have on our consolidated financial position, results of operations, cash flows, and related disclosures.
There were no other new accounting pronouncements that were issued or became effective since the issuance of our 2021 Annual Report on Form 10-K that had, or are expected to have, a material impact on our consolidated financial position, results of operations or cash flows.
3.    Business Acquisitions
Pending Acquisition
On November 10, 2021, we announced our entrance into an agreement with Personal Touch Holding Corporation to acquire Integra Managed Care (“Integra”). Integra is a managed long-term care plan that serves New York state Medicaid members, enabling adults with long-term care needs and disabilities to live safely and independently in their own home. The acquisition is expected to close by the end of the second quarter of 2022 and is subject to standard closing conditions and customary approvals.
-10-


Completed Acquisitions
Acquisitions completed during the year ended December 31, 2021, for which the initial accounting was not finalized as of March 31, 2022, included myNEXUS, Inc. (“myNEXUS”), a comprehensive home-based nursing management company for payors, and MMM Holdings, LLC (“MMM”), including its Medicare Advantage plan, Medicaid plan and other affiliated companies. As of March 31, 2022, the purchase price of each transaction was allocated to the tangible and intangible net assets acquired based on management’s final estimates of their fair values, of which $1,577 has been allocated to finite-lived intangible assets, $20 to indefinite-lived intangible assets, and $2,525 to goodwill. The majority of goodwill is not deductible for income tax purposes. Adjustments to goodwill arising from contractual purchase price adjustments and subsequent adjustments made to the assets acquired or liabilities assumed during the quarter ended March 31, 2022 were $4.
4.    Business Optimization Initiatives
Provided below is a summary of the activity, by reportable segment, related to the liability for employee termination costs previously incurred in connection with our enterprise-wide business optimization initiatives introduced in 2020.
Commercial & Specialty BusinessGovernment BusinessIngenioRxOtherTotal
2020 Business Optimization Initiatives
Employee termination costs:
Liability for employee termination costs at January 1, 2022$61 $57 $1 $3 $122 
Payments(5)(5)  (10)
Liability for employee termination costs at March 31, 2022
$56 $52 $1 $3 $112 
5.     Investments
Fixed Maturity Securities
We evaluate our available-for-sale fixed maturity securities for declines based on qualitative and quantitative factors. We have established an allowance for credit loss and recorded credit loss expense as a reflection of our expected impairment losses. We continue to review our investment portfolios under our impairment review policy. Given the inherent uncertainty of changes in market conditions and the significant judgments involved, there is a continuing risk that declines in fair value may occur and additional material impairment losses on investments may be recorded in future periods.
Although not material to our consolidated results of operations, during the three months ended March 31, 2022, we recorded a combination of credit losses, losses on sale of fixed maturity securities and impairments related to our exposure resulting from investments in Russia and Ukraine. These items are reflected in the tables presented below. At March 31, 2022, our remaining holdings of Russia and Ukraine fixed maturity securities were not material.

-11-


A summary of current and long-term fixed maturity securities, available-for-sale, at March 31, 2022 and December 31, 2021 is as follows:
Cost or Amortized CostGross
Unrealized
Gains
Gross
Unrealized
Losses
Allowance
For Credit
Losses
Estimated
Fair Value
 
March 31, 2022
Fixed maturity securities:
United States Government securities$2,145 $ $(78)$ $2,067 
Government sponsored securities54 2 (2) 54 
Foreign government securities343 2 (25)(3)317 
States, municipalities and political subdivisions5,369 84 (126) 5,327 
Corporate securities12,361 104 (491)(8)11,966 
Residential mortgage-backed securities4,262 18 (174)(2)4,104 
Commercial mortgage-backed securities82 1 (4) 79 
Other securities2,967 13 (79) 2,901 
Total fixed maturity securities$27,583 $224 $(979)$(13)$26,815 
December 31, 2021
Fixed maturity securities:
United States Government securities$1,443 $7 $(18)$ $1,432 
Government sponsored securities65 4 (1) 68 
Foreign government securities353 7 (13) 347 
States, municipalities and political subdivisions5,321 310 (10) 5,621 
Corporate securities12,044 401 (78)(4)12,363 
Residential mortgage-backed securities4,059 75 (35)(2)4,097 
Commercial mortgage-backed securities65 2 (3) 64 
Other securities2,907 24 (24) 2,907 
Total fixed maturity securities$26,257 $830 $(182)$(6)$26,899 

-12-


For fixed maturity securities in an unrealized loss position at March 31, 2022 and December 31, 2021, the following table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position: 
 Less than 12 Months12 Months or Greater
(Securities are whole amounts)Number of
Securities
Estimated
Fair Value
Gross
Unrealized
Loss
Number of
Securities
Estimated
Fair Value
Gross
Unrealized
Loss
March 31, 2022
Fixed maturity securities:
United States Government securities86 $1,801 $(66)20 $149 $(12)
Government sponsored securities25 21 (1)1 1 (1)
Foreign government securities
233 205 (15)95 54 (10)
States, municipalities and political subdivisions
1,140 2,088 (123)23 25 (3)
Corporate securities3,616 7,520 (423)532 620 (68)
Residential mortgage-backed securities1,547 3,142 (137)184 419 (37)
Commercial mortgage-backed securities21 51 (1)5 9 (3)
Other securities746 2,240 (70)84 183 (9)
Total fixed maturity securities7,414 $17,068 $(836)944 $1,460 $(143)
December 31, 2021
Fixed maturity securities:
United States Government securities
51 $990 $(11)27 $176 $(7)
Government sponsored securities
   1 1 (1)
Foreign government securities
188 143 (8)68 41 (5)
States, municipalities and political subdivisions
281 634 (9)8 16 (1)
Corporate securities
1,846 3,310 (57)403 485